LUP.F - Luye Pharma Group Ltd.

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Luye Pharma Group Ltd.

No. 15 Chuang Ye Road
High-tech Industrial Development Zone
Yantai 264003
China

http://www.luye.cn

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees4,417

Key Executives

NameTitlePayExercisedYear Born
Mr. Dian Bo LiuCo-Founder, Exec. Chairman, CEO and Head of Corp. Directions & StrategiesN/AN/A1966
Mr. Rong Bing YangCo-Founder & Vice Exec. ChairmanN/AN/A1966
Mr. Hui Xian YuanCo-Founder & Exec. DirectorN/AN/A1959
Ms. Yuan Yuan ZhuExec. DirectorN/AN/A1981
Mr. Yuan Chong LiuChief Financial OfficerN/AN/A1964
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Luye Pharma Group Ltd. develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and treatment for metastatic carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Tiandixin, a product used as an adjuvant therapy for malignant tumors, malignant hydrothorax and ascites, and respiratory infections; and Yitaida for acute promyelocytic leukemia and liver cancer. It also provides Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for the treatment of cancer pain; and Buprenorphine Transdermal Patch for the treatment of chronic pain. In addition, it offers Beixi, an acarbose capsule for diabetes; and Lutingnuo, a reduced glutathione injection for toxicity and injuries caused by ionizing radiation; Beitangning, a pioglitazone hydrochloride capsule to control blood glucose; Nuosen for acute upper digestive tract hemorrhage; and Sailimai for the treatment of diarrhea. Further, it provides Xuezhikang, a lipid adjusting capsule; Maitongna for cerebral edema and swelling caused by trauma; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. Additionally, it distributes, sells, and retails pharmaceutical drugs; manufactures and sells eggs; and provides business and investment consultation, as well as contract research, process development, and manufacturing services. The company also engages in the cultivation of herbs and sales of herbal medicines. The company was founded in 1994 and is headquartered in Yantai, the People's Republic of China. Luye Pharma Group Ltd. is a subsidiary of Luye Life Sciences Group Ltd.

Corporate Governance

Luye Pharma Group Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.